USA

News

FDA Approves Guerbet’s Dotarem® (gadoterate meglumine) for Pediatric Patients Younger Than Two Years

24.10.2017 20:16

Princeton (NJ, USA), September 5, 2017

Guerbet LLC USA, the US affiliate of the global specialist in contract products and solutions for medical imaging, announced today that the US Food and Drug Administration (FDA) has approved Dotarem® (gadoterate meglumine) for intravenous use with magnetic resonance imaging (MRI) in pediatric patients under two years old, including term neonates, to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS).

Dotarem was previously approved for this use in patient populations over the age of two.

The supplemental indication fulfills a post marketing requirement, acknowledged when Dotarem was first registered in March 2013, to strictly comply with the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c).

The FDA's review was based on a study showing that at the standard dose (0.1 mmol/kg)1 the pharmacokinetic (PK) and safety profiles in pediatric patients under two were similar to those of older children and adults.

The study enrolled 51 pediatric patients in nine centers, with ages spanning from term neonates to 23 months and with normal renal function. It evaluated 45 pediatric patients for PK profile and safety, including five subjects aged less than one month and nine subjects aged one to three months. It assessed efficacy in a subset of 28 subjects who underwent an MRI examination of brain, spine, and associated tissues. 

In this pediatric population the observed safety profile of Dotarem was consistent with what has been reported in older populations. In one patient, rash was reported as a moderate adverse event. Serious AEs unrelated to Dotarem were reported in one out of 45 patients. Evaluation of images from contrast-enhanced MRI of the CNS supported extrapolation of CNS efficacy findings reported in adults and older children.

"It is critical for Guerbet to help patients and their healthcare providers meet this medical need. We are committed to providing safe and effective contrast media to improve diagnosis of all populations including those who need special care, like young children. In fact, a study published earlier this year in Pediatric Radiology found that 80% of children's hospitals surveyed now use macrocyclic contrast agents2," said Massimo Carrara, VP North America.

Dotarem is the only macrocyclic and ionic gadolinium-based contrast medium (a kind that provides high molecular stability) available in the US.

To date, Dotarem is approved in 79 countries worldwide. More than 65 million doses of Dotarem have been administered since first launch. No unconfounded cases of NSF have been reported for Dotarem.